FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311705894> ?p ?o ?g. }

• W4311705894 abstract "Objective: Postherpetic neuralgia (PHN) is a clinical puzzle, especially in patients who still suffered from moderate and severe pain after standard treatment. This single-center, double-blinded, randomized controlled, prospective, and non-inferiority study observed the safety and effectiveness of the epidural application of morphine or hydromorphone, trying to provide an alternative method for those patients with refractory PHN. Methods: Eighty PHN patients with a visual analogue scale (VAS) still greater than 50 mm after routine management were randomly divided into two groups according to 1:1, respectively. One group received epidural morphine (EMO group), and the other group received epidural hydromorphone (EHM group). VAS, the number of breakthrough pain, quality of life (QOL), and anxiety/depression assessment (GAD-7 and PHQ-9 scores) were also observed before treatment, at 1, 3, 7, 14, 21, 28, 60, and 90 days after treatment, as well as side effects. Opioid withdrawal symptoms (OWSs) were also measured from 3 to 28 days after treatment. Results: The EHM group was non-inferior to the EMO group in terms of the VAS decrease relative to baseline (VDRB) after 1-week treatment. The VAS of the two groups on all days after treatment was significantly lower than the corresponding baseline findings ( p &lt; 0.05). The breakthrough pain (BTP) decreased significantly after treatment and lasted until 14 days after treatment ( p &lt; 0.05). There was no significant difference in BTP between the two groups at each time point ( p &gt; 0.05). In terms of the QOL, GAD-7, and PHQ-9 outcomes, those were significantly improved after treatment ( p &lt; 0.05), and there was no difference between the two groups ( p &gt; 0.05). No significant AE difference across the two groups was observed in this study. Few reports of OWS were found in this trial, and there were no significant differences between the two groups ( p &gt; 0.05). Conclusion: EHM was non-inferior to EMO in terms of the VDRB after 1-week treatment. For patients with VAS still greater than 50 mm after standard treatment, short-term application of EMO or EHM can ameliorate intractable pain, improve the quality of life, and have no obvious side effects. Short-term epidural opioid application will not lead to the appearance of OWS." @default.
• W4311705894 created "2022-12-28" @default.
• W4311705894 creator A5010849680 @default.
• W4311705894 creator A5014551687 @default.
• W4311705894 creator A5032241163 @default.
• W4311705894 creator A5057045813 @default.
• W4311705894 creator A5080000298 @default.
• W4311705894 creator A5081486308 @default.
• W4311705894 creator A5081754197 @default.
• W4311705894 creator A5085178611 @default.
• W4311705894 creator A5088596691 @default.
• W4311705894 date "2022-12-06" @default.
• W4311705894 modified "2023-10-02" @default.
• W4311705894 title "The efficacy and safety of epidural morphine/hydromorphone in the treatment of intractable postherpetic neuralgia: A single-center, double-blinded, randomized controlled, prospective, and non-inferiority study" @default.
• W4311705894 cites W1979744318 @default.
• W4311705894 cites W2012039532 @default.
• W4311705894 cites W2013434869 @default.
• W4311705894 cites W2026477615 @default.
• W4311705894 cites W2028934683 @default.
• W4311705894 cites W2056611380 @default.
• W4311705894 cites W2071419929 @default.
• W4311705894 cites W2073227598 @default.
• W4311705894 cites W2122540356 @default.
• W4311705894 cites W2135470636 @default.
• W4311705894 cites W2136743000 @default.
• W4311705894 cites W2170691735 @default.
• W4311705894 cites W2177389296 @default.
• W4311705894 cites W2327317502 @default.
• W4311705894 cites W2419479961 @default.
• W4311705894 cites W2561558711 @default.
• W4311705894 cites W2591605610 @default.
• W4311705894 cites W2618003115 @default.
• W4311705894 cites W2618712452 @default.
• W4311705894 cites W2739367075 @default.
• W4311705894 cites W2893160371 @default.
• W4311705894 cites W2912405124 @default.
• W4311705894 cites W2949882749 @default.
• W4311705894 cites W3000692550 @default.
• W4311705894 cites W3020124908 @default.
• W4311705894 cites W3036234541 @default.
• W4311705894 cites W3045128933 @default.
• W4311705894 cites W3111338444 @default.
• W4311705894 cites W3191514542 @default.
• W4311705894 cites W3200018714 @default.
• W4311705894 doi "https://doi.org/10.3389/fphar.2022.1051357" @default.
• W4311705894 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36561344" @default.
• W4311705894 hasPublicationYear "2022" @default.
• W4311705894 type Work @default.
• W4311705894 citedByCount "1" @default.
• W4311705894 countsByYear W43117058942023 @default.
• W4311705894 crossrefType "journal-article" @default.
• W4311705894 hasAuthorship W4311705894A5010849680 @default.
• W4311705894 hasAuthorship W4311705894A5014551687 @default.
• W4311705894 hasAuthorship W4311705894A5032241163 @default.
• W4311705894 hasAuthorship W4311705894A5057045813 @default.
• W4311705894 hasAuthorship W4311705894A5080000298 @default.
• W4311705894 hasAuthorship W4311705894A5081486308 @default.
• W4311705894 hasAuthorship W4311705894A5081754197 @default.
• W4311705894 hasAuthorship W4311705894A5085178611 @default.
• W4311705894 hasAuthorship W4311705894A5088596691 @default.
• W4311705894 hasBestOaLocation W43117058941 @default.
• W4311705894 hasConcept C121332964 @default.
• W4311705894 hasConcept C126322002 @default.
• W4311705894 hasConcept C141071460 @default.
• W4311705894 hasConcept C14184104 @default.
• W4311705894 hasConcept C142424586 @default.
• W4311705894 hasConcept C159110408 @default.
• W4311705894 hasConcept C168563851 @default.
• W4311705894 hasConcept C170493617 @default.
• W4311705894 hasConcept C2777107010 @default.
• W4311705894 hasConcept C2777389121 @default.
• W4311705894 hasConcept C2777610700 @default.
• W4311705894 hasConcept C2778866549 @default.
• W4311705894 hasConcept C2779158186 @default.
• W4311705894 hasConcept C2779951463 @default.
• W4311705894 hasConcept C2781063702 @default.
• W4311705894 hasConcept C42219234 @default.
• W4311705894 hasConcept C71924100 @default.
• W4311705894 hasConcept C87355193 @default.
• W4311705894 hasConceptScore W4311705894C121332964 @default.
• W4311705894 hasConceptScore W4311705894C126322002 @default.
• W4311705894 hasConceptScore W4311705894C141071460 @default.
• W4311705894 hasConceptScore W4311705894C14184104 @default.
• W4311705894 hasConceptScore W4311705894C142424586 @default.
• W4311705894 hasConceptScore W4311705894C159110408 @default.
• W4311705894 hasConceptScore W4311705894C168563851 @default.
• W4311705894 hasConceptScore W4311705894C170493617 @default.
• W4311705894 hasConceptScore W4311705894C2777107010 @default.
• W4311705894 hasConceptScore W4311705894C2777389121 @default.
• W4311705894 hasConceptScore W4311705894C2777610700 @default.
• W4311705894 hasConceptScore W4311705894C2778866549 @default.
• W4311705894 hasConceptScore W4311705894C2779158186 @default.
• W4311705894 hasConceptScore W4311705894C2779951463 @default.
• W4311705894 hasConceptScore W4311705894C2781063702 @default.
• W4311705894 hasConceptScore W4311705894C42219234 @default.
• W4311705894 hasConceptScore W4311705894C71924100 @default.
• W4311705894 hasConceptScore W4311705894C87355193 @default.
• W4311705894 hasLocation W43117058941 @default.
• W4311705894 hasLocation W43117058942 @default.
• W4311705894 hasLocation W43117058943 @default.

• next